High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.

Ty B Dunn, Daniel Borja-Cacho, Srinath Chinnakotla, Erik B Finger, Gerardo Tamayo, Priya Verghese, Youngki Kim, Carlos Manivel, Raja Kandaswamy, Arthur J Matas, Timothy L Pruett, Harriet Noreen, Peggy Krefting, David H Maurer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Desensitization therapies have been used with modest success in kidney transplantation. Some candidates, however, have such great breadth and depth of anti-HLA antibodies that they remain incompatible with potential donors. Bortezomib has been used without much success in desensitization regimens, but we hypothesized that its use during induction may be helpful in targeting antibody production by long-lived plasma cells. This report describes a high-risk positive crossmatch son-to-mother transplant that was performed after desensitization. The induction immunosuppression was supplemented with bortezomib. Pre- and post-transplant immunosuppression, antibody monitoring, biopsy data, and the clinical course are described in detail. Following transplant, the patient had excellent early graft function. Serial biopsies did not reveal acute antibody mediated rejection. Despite excellent graft function, the patient underwent withdrawal of care and died due to complications of calciphylaxis and deconditioning. This case details the first report of bortezomib used as part of induction therapy in solid organ transplant. Donor specific antibody production remained stable after transplant, with near complete abrogation of class I specificities. There were no bortezomib-related complications.

Original languageEnglish (US)
Pages (from-to)381-387
Number of pages7
JournalClinical transplants
StatePublished - Dec 1 2011

Fingerprint

Living Donors
Transplants
Kidney
Antibodies
Immunosuppression
Antibody Formation
Calciphylaxis
Tissue Donors
Biopsy
Rejection (Psychology)
Bortezomib
Plasma Cells
Nuclear Family
Kidney Transplantation
Anti-Idiotypic Antibodies
Mothers
Therapeutics

Cite this

High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection. / Dunn, Ty B; Borja-Cacho, Daniel; Chinnakotla, Srinath; Finger, Erik B; Tamayo, Gerardo; Verghese, Priya; Kim, Youngki; Manivel, Carlos; Kandaswamy, Raja; Matas, Arthur J; Pruett, Timothy L; Noreen, Harriet; Krefting, Peggy; Maurer, David H.

In: Clinical transplants, 01.12.2011, p. 381-387.

Research output: Contribution to journalArticle

@article{97833bf70fbd4ad39effb373f8e04b8b,
title = "High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.",
abstract = "Desensitization therapies have been used with modest success in kidney transplantation. Some candidates, however, have such great breadth and depth of anti-HLA antibodies that they remain incompatible with potential donors. Bortezomib has been used without much success in desensitization regimens, but we hypothesized that its use during induction may be helpful in targeting antibody production by long-lived plasma cells. This report describes a high-risk positive crossmatch son-to-mother transplant that was performed after desensitization. The induction immunosuppression was supplemented with bortezomib. Pre- and post-transplant immunosuppression, antibody monitoring, biopsy data, and the clinical course are described in detail. Following transplant, the patient had excellent early graft function. Serial biopsies did not reveal acute antibody mediated rejection. Despite excellent graft function, the patient underwent withdrawal of care and died due to complications of calciphylaxis and deconditioning. This case details the first report of bortezomib used as part of induction therapy in solid organ transplant. Donor specific antibody production remained stable after transplant, with near complete abrogation of class I specificities. There were no bortezomib-related complications.",
author = "Dunn, {Ty B} and Daniel Borja-Cacho and Srinath Chinnakotla and Finger, {Erik B} and Gerardo Tamayo and Priya Verghese and Youngki Kim and Carlos Manivel and Raja Kandaswamy and Matas, {Arthur J} and Pruett, {Timothy L} and Harriet Noreen and Peggy Krefting and Maurer, {David H}",
year = "2011",
month = "12",
day = "1",
language = "English (US)",
pages = "381--387",
journal = "Clinical transplants",
issn = "0890-9016",
publisher = "UCLA Immunogenetics Center",

}

TY - JOUR

T1 - High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.

AU - Dunn, Ty B

AU - Borja-Cacho, Daniel

AU - Chinnakotla, Srinath

AU - Finger, Erik B

AU - Tamayo, Gerardo

AU - Verghese, Priya

AU - Kim, Youngki

AU - Manivel, Carlos

AU - Kandaswamy, Raja

AU - Matas, Arthur J

AU - Pruett, Timothy L

AU - Noreen, Harriet

AU - Krefting, Peggy

AU - Maurer, David H

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Desensitization therapies have been used with modest success in kidney transplantation. Some candidates, however, have such great breadth and depth of anti-HLA antibodies that they remain incompatible with potential donors. Bortezomib has been used without much success in desensitization regimens, but we hypothesized that its use during induction may be helpful in targeting antibody production by long-lived plasma cells. This report describes a high-risk positive crossmatch son-to-mother transplant that was performed after desensitization. The induction immunosuppression was supplemented with bortezomib. Pre- and post-transplant immunosuppression, antibody monitoring, biopsy data, and the clinical course are described in detail. Following transplant, the patient had excellent early graft function. Serial biopsies did not reveal acute antibody mediated rejection. Despite excellent graft function, the patient underwent withdrawal of care and died due to complications of calciphylaxis and deconditioning. This case details the first report of bortezomib used as part of induction therapy in solid organ transplant. Donor specific antibody production remained stable after transplant, with near complete abrogation of class I specificities. There were no bortezomib-related complications.

AB - Desensitization therapies have been used with modest success in kidney transplantation. Some candidates, however, have such great breadth and depth of anti-HLA antibodies that they remain incompatible with potential donors. Bortezomib has been used without much success in desensitization regimens, but we hypothesized that its use during induction may be helpful in targeting antibody production by long-lived plasma cells. This report describes a high-risk positive crossmatch son-to-mother transplant that was performed after desensitization. The induction immunosuppression was supplemented with bortezomib. Pre- and post-transplant immunosuppression, antibody monitoring, biopsy data, and the clinical course are described in detail. Following transplant, the patient had excellent early graft function. Serial biopsies did not reveal acute antibody mediated rejection. Despite excellent graft function, the patient underwent withdrawal of care and died due to complications of calciphylaxis and deconditioning. This case details the first report of bortezomib used as part of induction therapy in solid organ transplant. Donor specific antibody production remained stable after transplant, with near complete abrogation of class I specificities. There were no bortezomib-related complications.

UR - http://www.scopus.com/inward/record.url?scp=84864102563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864102563&partnerID=8YFLogxK

M3 - Article

SP - 381

EP - 387

JO - Clinical transplants

JF - Clinical transplants

SN - 0890-9016

ER -